Literature DB >> 31687869

Age-stratified analysis of serotype-specific baseline immunity against group B streptococcus.

Min Joo Choi1, Ji Yun Noh2, A-Yeung Jang2, Hee Jin Cheong2, Woo Joo Kim2, Dae Jin Song3, Geum Joon Cho4, Min Jeong Oh4, Yong Zhi5,6, Ho Seong Seo5,6, Joon Young Song2.   

Abstract

Group B streptococcus (GBS) vaccines are currently under development. Data on the natural immunity in diverse age groups will aid establishing the GBS immunization policy. In this study, thirty serum samples were collected from three age groups (neonates/infants, pregnant women, and the elderly) between August 2016 and July 2017. Serotype-specific opsonophagocytic activity (OPA) was assessed using a GBS multiplex opsonophagocytic killing assay (MOPA) against serotypes Ia, III, and V. The mean OPA titers for serotype Ia of the three age groups were not significantly different (p = .156), but tended to be lower in neonates/infants (mean ± standard deviation, 137 ± 278). For serotype III and V, the mean OPA titer of neonates/infants (338 ± 623 and 161 ± 445, respectively) was significantly lower than that of pregnant women (1377 ± 1167 and 9414 ± 6394) and the elderly (1350 ± 1741 and 3669 ± 5597) (p = .002). In conclusion, the lower levels of OPA titers against all tested serotypes in neonates/infants, despite high maternal titers, indicates that intrapartum GBS vaccinations may be required for efficient placental transfer of serotype-specific GBS antibodies with high avidity.

Entities:  

Keywords:  Streptococcus agalactiae ; GBS; group B streptococcus ; immunity; immunoassay; opsonophagocytic killing assay

Year:  2019        PMID: 31687869      PMCID: PMC7482737          DOI: 10.1080/21645515.2019.1688036

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  39 in total

1.  Comparison of PCR and serotyping of Group B Streptococcus in pregnant women: the Oslo GBS-study.

Authors:  Anne Karin Brigtsen; Lumnije Dedi; Kjetil K Melby; Mona Holberg-Petersen; Andreas Radtke; Randi Valsø Lyng; Lise Lima Andresen; Anne Flem Jacobsen; Drude Fugelseth; Andrew Whitelaw
Journal:  J Microbiol Methods       Date:  2014-11-13       Impact factor: 2.363

2.  Detection and genomic analysis of genital group B streptococcus in pregnant Korean women.

Authors:  Hwan Tae Lee; Suk Young Kim; Pil-Whan Park; Jeong-Yeal Ahn; Kyung-Hee Kim; Ja Young Seo; Ji-Hun Jeong; Woo-Jae Kwoun; Yiel-Hea Seo
Journal:  J Obstet Gynaecol Res       Date:  2018-09-19       Impact factor: 1.730

3.  Dose-response to type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine in healthy adults.

Authors:  Carol J Baker; Marcia A Rench; Lawrence C Paoletti; Morven S Edwards
Journal:  Vaccine       Date:  2006-07-31       Impact factor: 3.641

4.  Level of maternal antibody required to protect neonates against early-onset disease caused by group B Streptococcus type Ia: a multicenter, seroepidemiology study.

Authors:  F Y Lin; J B Philips; P H Azimi; L E Weisman; P Clark; G G Rhoads; J Regan; N F Concepcion; C E Frasch; J Troendle; R A Brenner; B M Gray; R Bhushan; G Fitzgerald; P Moyer; J D Clemens
Journal:  J Infect Dis       Date:  2001-08-31       Impact factor: 5.226

5.  Specific involvement of pilus type 2a in biofilm formation in group B Streptococcus.

Authors:  Cira Daniela Rinaudo; Roberto Rosini; Cesira L Galeotti; Francesco Berti; Francesca Necchi; Valerio Reguzzi; Claudia Ghezzo; John Laird Telford; Guido Grandi; Domenico Maione
Journal:  PLoS One       Date:  2010-02-15       Impact factor: 3.240

6.  Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines.

Authors:  Carol J Baker; Lawrence C Paoletti; Marcia A Rench; Hilde-Kari Guttormsen; Morven S Edwards; Dennis L Kasper
Journal:  J Infect Dis       Date:  2004-03-01       Impact factor: 5.226

Review 7.  Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early- and late-onset invasive disease in young-infants.

Authors:  Shabir A Madhi; Ziyaad Dangor; Paul T Heath; Stephanie Schrag; Alaine Izu; Ajoke Sobanjo-Ter Meulen; Peter M Dull
Journal:  Vaccine       Date:  2013-08-28       Impact factor: 3.641

8.  Opsonophagocytic Antibodies to Serotype Ia, Ib, and III Group B Streptococcus among Korean Infants and in Intravenous Immunoglobulin Products.

Authors:  Han Wool Kim; Ji Hyen Lee; Hye Kyung Cho; Hyunju Lee; Ho Seong Seo; Soyoung Lee; Kyung Hyo Kim
Journal:  J Korean Med Sci       Date:  2017-05       Impact factor: 2.153

9.  Protective effect of Group B Streptococcus type-III polysaccharide conjugates against maternal colonization, ascending infection and neonatal transmission in rodent models.

Authors:  Emiliano Chiarot; Angela Spagnuolo; Silvia Maccari; Eleonora Naimo; Alessandra Acquaviva; Raffaella Cecchi; Bruno Galletti; Monica Fabbrini; Elena Mori; Paolo Ruggiero; Guido Grandi; Maria Rita Fontana; Giuliano Bensi; Immaculada Margarit
Journal:  Sci Rep       Date:  2018-02-07       Impact factor: 4.379

10.  Prevalence of group B streptococcus colonization in pregnant women in a tertiary care center in Korea.

Authors:  Da Hyun Kim; Byoung Jin Min; Eun Jung Jung; Jung Mi Byun; Dae Hoon Jeong; Kyung Bok Lee; Moon Su Sung; Ki Tae Kim; Young Nam Kim
Journal:  Obstet Gynecol Sci       Date:  2018-08-09
View more
  2 in total

1.  Safety Analysis of Apatinib Combined with Chemotherapy in the Treatment of Advanced Gastric Carcinoma: A Randomised Controlled Trial.

Authors:  Min Yuan; Zhaohui Wang; Yibo Zhang; Liying Chen; Yuting Liu; Cui Cui; Bo Sun
Journal:  J Oncol       Date:  2021-08-09       Impact factor: 4.375

2.  Development and Validation of Enzyme-Linked Immunosorbent Assay for Group B Streptococcal Polysaccharide Vaccine.

Authors:  A-Yeung Jang; Min-Joo Choi; Yong Zhi; Hyun-Jung Ji; Ji-Yun Noh; Jin-Gu Yoon; Hee-Jin Cheong; Woo-Joo Kim; Ho-Seong Seo; Joon-Young Song
Journal:  Vaccines (Basel)       Date:  2021-05-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.